Tularik Inc. (TLRK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (383)	1/8/2003 8:28:19 PM
From: keokalani'nui	Read Replies (1) of 598

Yeah, it was Goeddel. As for P2 CXCR5 4Q03, maybe there is a dose range planned before that. I am certain he said the PoC in sick patients will start 4Q03. Coulda missed it though. Someone who reviews the archive please clarify. He spend a little longer than usual explaining why HCC is a good target for T67 and a big market and an easy market and all that. Better than in the past. As for no SEs in P1 CXCR3, he choked a bit at that point; but I'm pretty sure the take-away is its totally clean for all practical purposes. OK, maybe a really picky SOB might disagree with one incidence........or something like that. W

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next